Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft is now in use at >150 U.S. hospitals, after market launch in late 1H16.
Last month, the company announced two-year follow-up data from an FDA Investigational Device Exemption trial of i-FACTOR, showing statistic superiority to autograft in overall clinical success in cases of anterior cervical discectomy and fusion.
The product’s 2015 premarket approval represented the first PMA for bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine overall, following Medtronic’s INFUSE.
Cerapedics' i-FACTOR™ Peptide Enhanced Bone Graft is now in use at >150 U.S. hospitals, after market launch in late 1H16.
Last month, the company announced two-year follow-up data from an FDA Investigational Device Exemption trial of i-FACTOR, showing statistic superiority to autograft in overall clinical success in cases of anterior...
Cerapedics’ i-FACTOR™ Peptide Enhanced Bone Graft is now in use at >150 U.S. hospitals, after market launch in late 1H16.
Last month, the company announced two-year follow-up data from an FDA Investigational Device Exemption trial of i-FACTOR, showing statistic superiority to autograft in overall clinical success in cases of anterior cervical discectomy and fusion.
The product’s 2015 premarket approval represented the first PMA for bone graft for use in the cervical spine, and the second PMA-approved bone graft in the spine overall, following Medtronic’s INFUSE.
Copy to clipboard 
